AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04093986 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Women who choose to participate directly and provide information in survey format will receive a brief survey and the option to upload their medical records (if available) into Cincinnati Children's maintained REDCap database.
Study NCT01331928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine (Xeloda, Roche), Oxaliplatin (Sanofi-Aventis), Docetaxel (Sanofi-Aventis)
Description: capecitabine orally 1000 mg/m2 twice daily, day1 to day 10, every 2 weeks plus oxaliplatin 85mg/m2 (2hrs IV infusion)on day1, every 2 weeks for 6 cycles, then shift to docetaxel 30 mg/m2(over 30-minute intravenous infusion) on day 1 and day 8 plus oral capecitabine 825 mg/m2 twice daily on day 1 to 14, every 3 weeks for 4 cycles.
Study NCT04422054 — intervention group
Intervention type: PROCEDURE
Intervention: Open Surgery
Description: We will retrospectively review patients with abdominal aortic aneurysms that underwent open surgical repair.
Study NCT04422054 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular Surgery
Description: We will retrospectively review patients with abdominal aortic aneurysms that underwent endovascular repair.
Study NCT01091818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Dexemedethomidine is given as major sedative drug
Study NCT01091818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam is given as major sedative drug
Study NCT04087707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Step 1: TS-142
Description: Non-elderly participants will receive 20 mg of TS-142 once daily for 7 consective days
Study NCT04087707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Step 2: TS-142
Description: Elderly participants will receive 20 mg of TS-142 once daily for 7 consective days
Study NCT04087707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Step 2: TS-142
Description: Elderly participants will receive 20 mg of TS-142 once daily for 7 consective days
Study NCT04087707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Step 2: Placebo
Description: Elderly participants will receive placebo once daily for 7 consective days
Study NCT04087707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Step 2: Placebo
Description: Elderly participants will receive placebo once daily for 7 consective days
Study NCT03006276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-15 Active
Study NCT03006276 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DFN-15 Placebo
Study NCT02490111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1319
Study NCT02490111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02490111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04306003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS pathway
Description: See ERAS pathway arm description.
Study NCT04306003 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Perioperative Care
Description: See control arm description.
Study NCT02715089 — intervention group
Intervention type: GENETIC
Intervention: Precise treatment
Description: During screening stage, all patients should accept next-generation sequencing (NGS) test.
Study NCT01968629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eovist
Study NCT02303470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vigorous Exercise
Description: High-intensity interval training alternates 30 seconds of vigorous exercise with 30 seconds of low-intensity recovery for a total of 15 minutes.
Study NCT02303470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Exercise
Study NCT02948998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: The participants in this arm will be prescribed to take 20mg spironolactone orally and daily. Serum potassium concentration and creatinine and blood pressure will be monitored regularly to make the participants safe.
Study NCT02254694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high heeled shoes
Description: see detailed study description
Study NCT03033290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bu-Zhong-Yi-Qi-Tang
Description: Qi-tonifying regimen of traditional Chinese herbal medicine
Study NCT03033290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo control
Study NCT00665002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WT-1
Description: Immune responses were to be evaluated at weeks 6 and 12 via delayed-type hypersensitivity, CD4 T cell proliferation, CD4 and CD8 T cell interferon release, as well as by bone marrow cytogenetics including polymerase chain reaction (PCR) to look for molecular evidence of disease. Patients who had an immunologic response and had not had disease progression could continue with up to 6 more vaccinations administered approximately every month. In that case, patients were to be reevaluated with bone marrows/immunologic studies after the 9th and 12th vaccination. In addition, patients would undergo evaluations for residual disease including immunohistochemistry and/or quantitative polymerase chain reaction (RQ-PCR) for WT-1 expression (on selected patients), and multiparameter flow cytometry (AML/ MDS).
Study NCT01075503 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: brachial plexus block
Description: 0.5% Ropivacaine 40ml
Study NCT00665002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide
Description: The WT-1 vaccine is given with another substance, called Montanide, which clumps the WT-1 vaccine and thereby improves the immune response.
Study NCT00665002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (GM-CSF)
Description: GM-CSF was administered at a dose 70 mcg (140ul) as a subcutaneous injection at the site of vaccination on day -2 and day 0.
Study NCT01652027 — intervention group
Intervention type: DRUG
Intervention: FVIII concentrate
Description: usual treatment as directed by treating physician
Study NCT03343990 — intervention group
Intervention type: PROCEDURE
Intervention: Interlocking multi-twisted wires in sternal closure
Description: One of many ways in cloure of sternal give more stabilization. At least 6 wires have to be passed. The wirs should run around the sternum in the intercostals spaces except in the manubrium where it has to be passed through the bone . Adjacent wires on the surgeon's side are wrapped around each other. The wires on the surgeon's side are then pulled towards the assistant so that the sternum is re-approximated. Alternatively the surgeon can also pull the wires at the assistant's side towards himself or herself approximating the sternum. Adjacent wires on the assistant's side are then wrapped around each other. The wrapped wires on both sides are then wrapped around each other The wrapped wires are then twisted around with a twister, closing the sternum tightly and the ends of the are burried
Study NCT03343990 — intervention group
Intervention type: PROCEDURE
Intervention: Eight Figure techniqe in sternal closure
Description: The figure-eight closure is described as faster, simpler, and more reliable than its trans-sternal counterpart; with only oblique forces sutures are less likely to loosen or fracture the sternum. The advantage of figure-eight closure is that it allows oblique and horizontal angle of shearing forces instead of direct perpendicular forces. Thus these wires are less likely to loosen or fracture
Study NCT01464073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIPOXmax
Description: Arm 1: LIPOXmax arm. Subjects will perform a physical activity 4x1 hour per week at the optimal intensity for fat oxidation (LIPOXmax) measured by indirect calorimeter.
Study NCT01464073 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 60% VO2peak
Description: Arm 2: physical activity standard arm (60% of VO2max measured by cardio respiratory exercise test). Subjects will realize 4 sessions per week and duration of sessions will be adjusted so that arms 1 and 2 have the same total energy expenditure by session.
Study NCT01464073 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Good Medical Practices
Description: Arm 3: The subjects initially receive the recommendations of good medical practice for physical activity (achieving at least 30min per day of moderate exercise).
Study NCT01464073 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplementation in fruits and vegetables
Description: all groups will be supplemented in fruits and vegetables (5 per day) during all the study
Study NCT01464073 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: supplementation in fruits and vegetables
Description: all groups will be supplemented in fruits and vegetables (5 per day) during all the study
Study NCT01075503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: brachial plexus block
Description: 0.5% Ropivacaine 40ml
Study NCT04518865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Herbst appliance
Description: The bottom line of the study is to investigate the changes after Herbst appliance treatment and relate it to the pubertal status of the skeletal class II patients using CBCT.
Study NCT00211926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate
Description: single dose of vaccine containing 100 mcg of each serotype conjugate
Study NCT00211926 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose of placebo
Study NCT03867656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-2
Description: GLP-2 injection
Study NCT03867656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP
Description: GIP injection
Study NCT03867656 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection
Study NCT01641848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INBONE™ Total Ankle Prosthesis with Long Talar Stem
Description: INBONE™ Total Ankle Prosthesis with Long Talar Stem when used with a Calcaneal Stem
Study NCT03104712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spaghetti + Tomato Sauce
Description: 50g available carbohydrate
Study NCT03104712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice + Tomato Sauce
Description: 50g available carbohydrate
Study NCT03194438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Urban Zen Integrative Therapy (UZIT)
Description: Multi-modal components integrative therapy program (UZIT) that includes essential oil, gentle body movement, body-awareness meditation, and Reiki.
Study NCT04319887 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evoke Spinal Cord Stimulation (SCS) System
Description: A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
Study NCT02707796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemicolectomy
Study NCT00708734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: functional exercise training
Description: twice weekly group sessions for 5 weeks
Study NCT04070495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356
Description: A single oral dose will be administered at Day 1 and 15
Study NCT04070495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 400mg, oral tablet (2 x 200mg), twice daily (BID), Day 8-28
Study NCT04070495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: 600mg, oral tablet (4 x 150mg), once daily (QD), Day 8-21
Study NCT01252524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet po TID before each meal with 8 oz of water for 6 months
Study NCT01252524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium polycarbophil
Description: calcium polycarbophil 625 mg po TID before each meal with 8 oz water for 6 months
Study NCT02942654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered subcutaneously (SC)
Study NCT03104712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spaghetti + Pesto
Description: 50g available carbohydrate
Study NCT03104712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice + Pesto
Description: 50g available carbohydrate
Study NCT04574570 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: High Tibial Osteotomy
Description: Personalised High Tibial Osteotomy (HTO) using a patient-specific fixation plate (TOKA®)
Study NCT00098423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV
Study NCT00098423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT03338426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan 120mg
Description: Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
Study NCT03338426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan 120mg
Description: Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
Study NCT03338426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 40mg
Description: Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period
Study NCT03338426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg
Description: Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period
Study NCT03338426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Fimasartan 120mg
Description: Placebo for Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
Study NCT02942654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study NCT02334397 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Total Control Program
Description: Women will be enrolled in Total Control, which is a fitness and education program.
Study NCT03338426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Atorvastatin 40mg
Description: Placebo for Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period
Study NCT00371254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 100 mg, twice daily as long as the patient benefits (avg \<6 months)
Study NCT00371254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 70 mg, twice daily as long as the patient benefits (avg \<6 months)
Study NCT04409743 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Remote Cognitive Behavioral Therapy for Insomnia
Description: Participants will meet with a psychologist through telehealth once a week for four weeks to complete a brief CBT-I intervention. Cognitive Behavioral Therapy for Insomnia consists of a cognitive therapy and a behavioral therapy. The cognitive therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep. The behavioral therapy increases sleep quality by limiting excessive time spent in bed to increase homeostatic sleep drive and sleep consolidation.
Study NCT04409743 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Remote Cognitive Behavioral Therapy for Insomnia
Description: Participants will meet with a psychologist through telehealth once a week for four weeks to complete a brief CBT-I intervention. Cognitive Behavioral Therapy for Insomnia consists of a cognitive therapy and a behavioral therapy. The cognitive therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep. The behavioral therapy increases sleep quality by limiting excessive time spent in bed to increase homeostatic sleep drive and sleep consolidation.
Study NCT01990495 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Subjects will participate in a center-based and home exercise training program for 3 months.
Study NCT01990495 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: This group will serve as control subjects. They will receive only usual clinical care.
Study NCT04109729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480mg IV every 4 weeks for up to 2 years~• Radium-223 55 kBq/kg IV q4 weeks for 6 cycles total
Study NCT02808416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized cellular vaccine
Description: Cancer patients with brain metastases will undergo tumor resection or biopsy, and receive tumor antigen mRNA pulsed cellular vaccines.~Other Names:~• Tumor antigen pulsed DC and PBMC, autologous tumor vaccine
Study NCT00325754 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E-Cylinder
Description: Portable Oxygen Therapy Delivered Via An E-Cylinder Mounted On A Wheeled Cart
Study NCT00325754 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lightweight Cylinder
Description: Ambulatory Oxygen Therapy Delivered Via A Carbon-Wrapped Aluminum Cylinder
Study NCT00982709 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic vs. Agility Training
Description: High Intensity 4x's per week for 4 weeks with a physical therapist.
Study NCT01334723 — intervention group
Intervention type: DRUG
Intervention: Adherent with 5-alpha-reductase inhibitor (5ARI) therapy
Description: Patient with BPH who are adherent to 5ARI therapy (Adherence will be calculated using a medication possession ratio (MPR); 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
Study NCT01334723 — intervention group
Intervention type: DRUG
Intervention: Non-adherent to 5ARI therapy
Description: Patients with BPH non-adherent to 5ARI therapy (Adherence will be calculated using a MPR; 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
Study NCT01912144 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Coffee
Study NCT02912026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV F901318
Description: Metabolic profile AUC 0 to infinity
Study NCT02912026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral F901318
Description: Metabolic profile AUC 0 to infinity
Study NCT04139707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caring4Dementia
Description: A mobile application administered for 30 days, which provides people caring for a person living with dementia with a useful and intuitive tool targeting communication skills.
Study NCT04139707 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White Paper
Description: The White Paper group will receive a white paper (hard copy and electronically) on the principles of communicating efficiently with persons living with dementia.
Study NCT01586507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ULTRAM ER
Description: One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
Study NCT01586507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ULTRAM ER
Description: The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
Study NCT01190995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 24% Sucrose
Description: The enrolled neonates will be administered either a sterile solution of 24 % sucrose or double distilled water orally for a period of 7 days from enrollment. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
Study NCT01190995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient will be enrolled into the study only after an informed written consent has been obtained from either of the parent/caregiver. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure